Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2002

View Archived Issues

Phase III data demonstrate utility of MS-325 for enhancing MRA of vascular occlusive disease

Novel class of anti-HIV agents under evaluation at Rega Institute

Viramidine as an effective and safe liver-targeting ribavirin prodrug

SOD mimetic exerts potent anti-HIV activity and inhibits astrocyte apoptosis

Nucleoside inhibitors of HIV replication presented in Prague by U.S. university researchers

Potent analgesic effect demonstrated for duloxetine in an animal model of persistent pain

Greater global improvement in lipoprotein profiles obtained on new lipid-modifying combination

Cell death pathways activated by BMS-247550 in refractory ovarian cancer cells

Cellegy updates 2001 progress and outlook for 2002

Japanese filing made for sevelamer

ISTA updates clinical progress of Vitrase

Genaera highlights key clinical achievements of 2001

First European country approves Elidel for atopic dermatitis

WX-UK1 safe and well tolerated in phase Ia trial

Biovail acquires rights to Teveten in U.S.

Betaferon therapy shows sustained benefits and tolerability over 12 years

Comparative study of Thymoglobulin and Simulect in kidney transplant rejection closed early

Celgene develops new class of SERM with potential as both antiosteoporotic and anticancer agents

Avidex breakthrough in monoclonal T-cell receptor technology in cancer

Oxford GlycoSciences progress report

New antibacterial compounds reported by Aventis

Lilly describes new series of factor Xa inhibitors

Bristol-Myers Squibb presents new compounds for the treatment of thrombosis

FSH receptor agonists for in vitro fertilization patented by Affymax

Novel contraceptives identified by scientists at Affymax

PARP inhibitors and their uses presented by Ono

Fidia's new coumarin derivatives claimed for the treatment of vasculopathies, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...